Premium
Somatic genome alterations in triple‐negative breast cancer
Author(s) -
Meyerson Matthew
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.328.2
Subject(s) - triple negative breast cancer , breast cancer , cancer , estrogen receptor , exome sequencing , somatic cell , biology , genome , progesterone receptor , cancer research , oncology , medicine , genetics , gene , mutation
Breast cancer is the most common cause of cancer in women in the United States. Within breast cancer, the “triple‐negative” subtype, which is negative for estrogen receptor and progesterone receptor expression and negative for ERBB2 amplification, is the most deadly and has the fewest targeted therapies. Triple‐negative breast cancer occurs more commonly in young women and in women of African‐American descent. Identification of somatic genome alterations in cancer has led to development of many targeted therapies. To find such alterations in triple‐negative breasst cancer, we and others have performed systematic high‐throughput sequencing of genomes, exomes, and transcriptomes of these cancers. Here, I will discuss results from our studies, including AKT3 translocation in breast cancer, from The Cancer Genome Atlas, and other studies.